Navigation Links
Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC
Date:5/31/2011

In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome (HUS) after an infection with enterohemorrhagic Escherichia coli (EHEC). The infections occurred in 2010. EHEC are the bacteria that cause the current wave of infections that have already claimed ten lives in Germany. The number of suspected and confirmed cases of EHEC has now reached 700.

Eculizumab has been approved in Germany since 2007 and is used to treat a rare blood disease and a rare congenital form of HUS. Two years ago, American physicians reported similar success in children with this form of HUS (NEJM 2009; 360:544-546).

The children suffered from kidney failure and severe neurological disorders. "After several exchanges of blood plasma had no effect, we decided to attempt treatment with Eculizumab," reports Professor Dr. Franz Schaefer, head of the section of Pediatric Nephrology at the Center for Child and Adolescent Medicine at Heidelberg University Hospital.

Within 24 hours of the initial infusion, which was repeated once or twice at intervals of seven days, the clinical condition of the children improved dramatically. Dialysis due to acute kidney failure from HUS could be discontinued. All three children recovered and had no sequelae even six months after the illness.

The researchers decided on using the monoclonal antibody Eculizumab as it interrupts the destructive immune reactions that occur after an infection with EHEC. Eculizumab binds to protein C5, which activates what is called the complement cascade and lead to the destruction of blood cells among other things. With EHEC infections there can also be complement activation, triggered by the Shiga toxin formed by the bacteria.

"We now hope that these results will help the acutely ill patients," said Professor Schaefer. He assumes that even adult patients can profit from therapy with the antibody. "Because of the epidemic in Germany, the publishers of the New England Journal of Medicine decided to accelerate the publishing date of the article, which they have had since February, and they published it immediately after reviewing it," said Schaefer. In addition, the article was sent to all kidney specialists in Germany.

Meanwhile, first treatments of adults and children in German hospitals have started. The German Society of Nephrologists has issued guidelines that the antibody may be given if all others standard treatments like dialysis and plasmapheresis have failed.


'/>"/>

Contact: Dr. Annette Tuffs
annette.tuffs@med.uni-heidelberg.de
49-622-156-4536
University Hospital Heidelberg
Source:Eurekalert  

Related medicine news :

1. Accurate interpretation of antinuclear antibodies test key to confirming autoimmune disease
2. Why so many antibodies fail to protect against HIV infection
3. Novel autoantibodies identified in patients with necrotizing myopathy
4. Manmade antibodies hold biomedical promise
5. Antibodies linked to cardiovascular disease increase in patients with active lupus
6. Low levels of natural antibodies behind stroke
7. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
8. Cryoablation used to successfully treat atrial fibrillation at the Montreal Heart Institute
9. Successful depression treatment of mothers has long-term effects on offspring
10. Mayo Clinic CPR efforts successful on man with no pulse for 96 minutes
11. Successful Schools May Help Keep Kids Out of Trouble
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Antibodies successful in the treatment of the hemolytic-uremic syndrome from EHEC
(Date:3/29/2017)... , ... March 29, 2017 , ... ... with wearing oral braces. "The rubber bands used in conjunction with my braces ... I decided to design a way to prevent this problem." The O.B.S. was ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... of Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee ... Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started ...
(Date:3/28/2017)... ... 2017 , ... A recent Bellwether Education Partners’ report begins ... must first improve teacher preparation program design. It then asserts that teacher-education programs ... of input- and outcome-based research has failed to improve teacher education. , This ...
(Date:3/28/2017)... MN (PRWEB) , ... March 28, 2017 , ... ... (MRE), is pleased to be invited to the Siemens Healthineers annual customer ... professionals. The event will take place from March 27 - 31, 2017 ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... ... process management software and services, is proud to announce it has joined the ... professional association representing the interests of chronically ill, disabled, and dying Americans of ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DIEGO , March 29, 2017  NuVasive, ... focused on transforming spine surgery with minimally disruptive, ... Administration (FDA) 510(k) clearance of the CoRoent® Small ... multiple contiguous levels in the cervical spine. This ... cage to be used at up to four ...
(Date:3/29/2017)... March 29, 2017 On March 28, the U.S. Food ... patients with relapsing forms of multiple sclerosis (MS) and ... drug approved by the FDA for PPMS. Ocrevus is ... "Multiple sclerosis can have a profound ... , M.D., director of the Division of Neurology Products ...
(Date:3/29/2017)... Connecticut , March 29, 2017 ... company Sectra (STO: SECT B) announces ... will install Sectra PACS in their healthcare enterprise. ... the Epic EMR, will enable access and sharing ... pathway. Additionally, UPHS and Sectra will enter into ...
Breaking Medicine Technology: